Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALESSE vs BYSANTI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Ig G1κ monoclonal antibody that binds to the neonatal Fc receptor (Fc Rn), reducing Fc Rn-mediated recycling of Ig G, thereby lowering circulating Ig G levels including pathogenic Ig G autoantibodies.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in women ≥15 years who have achieved menarche and desire contraception),Contraception in women with heavy menstrual bleeding (off-label)
FDA: Treatment of generalized myasthenia gravis (g MG) in adult patients who are anti-acetylcholine receptor (ACh R) antibody positive.,Off-label: Not indicated for other conditions.
One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.
Initial dose 2 mg subcutaneously twice daily; after 3 months, increase to 4 mg subcutaneously twice daily based on clinical response and tolerability.
Levonorgestrel: terminal half-life ~17-20 hours (range 11-25 hr). Ethinyl estradiol: biphasic; terminal half-life ~13-27 hours (mean ~17 hr). Clinical context: steady-state achieved within 5-7 days. The half-life supports once-daily dosing with at least 24-hour contraceptive coverage.
Terminal elimination half-life: 64-104 hours (mean 84 hours). Clinical context: Supports once-daily dosing; steady-state achieved in ~2-3 weeks.
Ethinyl estradiol is primarily metabolized by CYP3A4 and undergoes conjugation (glucuronidation and sulfation). Levonorgestrel is metabolized by CYP3A4 and reduction, with conjugation to glucuronide and sulfate conjugates.
Degraded by general proteolysis into small peptides and amino acids; not metabolized by cytochrome P450 enzymes.
Renal: ethinyl estradiol (UE2) and levonorgestrel (LNG) metabolites primarily excreted in urine (UE2: ~40% as sulfate and glucuronide conjugates; LNG: ~25% as glucuronides). Fecal/biliary: ~40% (UE2) and ~45% (LNG) eliminated in feces via bile. Unchanged drug excretion is negligible.
Biliary/fecal (55-65% as parent drug and metabolites); renal (30-40%, primarily as conjugated metabolites, <3% unchanged).
Levonorgestrel: 97-99% bound to albumin and sex hormone-binding globulin (SHBG). Ethinyl estradiol: 98-99% bound, primarily to albumin (98.5%), with minor binding to SHBG. Free fractions: LNG ~1%, UE2 ~1.0-1.5%.
>99% primarily to albumin.
Levonorgestrel: Vd ~1.8 L/kg (range 1.5-2.0 L/kg). Ethinyl estradiol: Vd ~2.5-3.5 L/kg (mean ~2.9 L/kg). Indicates extensive tissue distribution, including target organs (ovaries, endometrium, breast). Not clinically adjusted for obesity.
Approximately 30 L/kg (0.43 L/kg in humans based on 70 kg). Extensive extravascular distribution, particularly to the liver (target organ via OATP1B1 uptake).
Oral: levonorgestrel ~95-100% (highly bioavailable). Ethinyl estradiol ~45-55% (first-pass metabolism reduces bioavailability; interindividual variability due to gut wall and hepatic conjugation). Both are prodrugs requiring hydrolysis for activity.
Oral: 20-30% (variable; low due to first-pass metabolism in gut wall and liver).
No specific GFR-based dose adjustments are recommended; however, use with caution in patients with renal impairment due to potential fluid retention and hypertension.
No dose adjustment recommended for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease; use not recommended.
Contraindicated in patients with severe hepatic disease (Child-Pugh class C) or active liver disease. In mild to moderate impairment (Child-Pugh A or B), use only if benefits outweigh risks; no specific dose reduction guidelines are available.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use not recommended.
Approved for postmenarchal adolescents; same dosing as adults: one tablet orally once daily for 21 days followed by 7 days of placebo. No weight-based adjustments are recommended.
Not approved for use in pediatric patients. Safety and efficacy not established.
Not indicated for use in postmenopausal women; no specific geriatric dosing adjustments are necessary if used off-label, but consider increased risk of thrombotic events in older women.
No specific dose adjustment required based on age. Use caution due to potential for decreased renal function and increased sensitivity to adverse effects; monitor closely.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. The risk increases with age, particularly in women over 35 years, and with heavy smoking (≥15 cigarettes per day). Women over 35 who smoke should not use this medication.
WARNING: Increased risk of serious infections, including opportunistic infections. Due to its mechanism of reducing Ig G levels, BYSANTI may increase the risk of infections. Monitor for signs and symptoms of infection and withhold treatment if severe infection occurs.
Increased risk of thromboembolic disorders (venous and arterial),Cigarette smoking increases risk of cardiovascular events, especially in women over 35,Hepatic neoplasia (benign and malignant),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache/migraine,Depression,Uterine bleeding irregularities,Ocular lesions (e.g., retinal thrombosis),Carcinoma of the breast and reproductive organs (close monitoring in current or history of breast cancer)
Serious infections: Increased risk of infections, including opportunistic infections. If severe infection occurs, withhold therapy.,Hypersensitivity reactions: Monitor for infusion-related reactions (e.g., pyrexia, headache, hypertension).,Immunizations: Avoid live or live-attenuated vaccines during treatment.,Fetal risk: May cause fetal harm based on animal studies; advise females of reproductive potential of potential risk.
Breast cancer (current or history),Carcinoma of the endometrium or other estrogen-dependent neoplasia,Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Valvular heart disease with complications,Severe hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known or suspected pregnancy,Active liver disease or impaired liver function,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35 years of age
Hypersensitivity to efgartigimod alfa or any excipients.
No specific food restrictions. Grapefruit juice may slightly increase ethinyl estradiol levels but not clinically significant. High-fat meals do not affect absorption. Avoid excessive alcohol as it may impair compliance.
No specific food interactions are known with BYSANTI. However, grapefruit and other CYP3A4-modulating foods may affect co-administered medications, but not bimekizumab itself. Maintain a balanced diet as recommended for overall health.
Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Second and third trimester exposure may cause fetal adrenal suppression, hepatic dysfunction, and virilization of female genitalia due to progestin component (levonorgestrel). Increased risk of ectopic pregnancy if conception occurs during use.
No human data; animal studies insufficient. Based on mechanism (CGRP receptor antagonist), theoretical risk of fetal harm; avoid use in pregnancy, especially first trimester.
Excreted in breast milk. Levonorgestrel M/P ratio approximately 0.3–0.4. Small amounts of ethinyl estradiol present. May reduce milk production and quality due to estrogen component. Use only if benefit outweighs risk; consider alternative contraception. American Academy of Pediatrics considers it compatible with nursing.
No human data; present in animal milk. M/P ratio unknown. Not recommended during breastfeeding.
Contraindicated. No dose adjustments apply as drug must be discontinued immediately if pregnancy suspected or confirmed. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) not relevant due to contraindication.
No established dose adjustments; contraindicated in pregnancy due to potential risk.
ALESSE is a combined oral contraceptive (COC) containing ethinyl estradiol (20 mcg) and levonorgestrel (100 mcg). It is indicated for contraception and treatment of acne vulgaris in women aged ≥14. Monitor for thromboembolic events, especially in smokers >35 years. Assess for contraindications including migraines with aura, hypertension, and history of DVT/PE. Advise use of backup contraception if a pill is missed. Start on first day of menses or first Sunday after onset. Check BP at baseline and annually. Counsel on increased risk of VTE, especially in first year.
BYSANTI (bimekizumab) is a humanized monoclonal Ig G1 antibody that inhibits both IL-17A and IL-17F. For plaque psoriasis, the recommended dose is 320 mg (two subcutaneous injections) at weeks 0, 4, 8, 12, and then every 8 weeks. Assess for tuberculosis prior to initiation; latent TB must be treated before starting therapy. Monitor for new onset or exacerbation of inflammatory bowel disease; discontinue if symptoms occur. Can be used with or without methotrexate for psoriatic arthritis. Live vaccines are contraindicated during treatment.
Take one pill daily at the same time each day, even if you do not have sex.,Missed pill instructions: if late by <12 hours, take it as soon as remembered and continue schedule. If >12 hours, take missed pill (even if means taking two in one day) and use backup contraception for 7 days.,Possible side effects: nausea, breast tenderness, headache, breakthrough bleeding, especially in first 3 months.,Seek emergency care for signs of blood clot: leg pain/swelling, sudden chest pain, shortness of breath, severe headache, vision changes.,Do not smoke while on ALESSE, especially if over age 35, as it increases risk of serious cardiovascular events.,Inform your healthcare provider of all medications and supplements you take, as some (e.g., rifampin, anticonvulsants, St. John's wort) may reduce effectiveness.
BYSANTI is given as two injections under the skin, typically in the abdomen or thigh.,Tell your doctor if you have had tuberculosis or have been in close contact with someone with TB.,Do not receive live vaccines during treatment; non-live vaccines are acceptable.,Seek medical attention if you develop new or worsening stomach pain, diarrhea, or bloody stools.,Report any signs of infection (fever, chills, cough) as BYSANTI increases infection risk.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALESSE vs BYSANTI, answered by our medical review team.
ALESSE is a Estrogen/Progestin Combination Contraceptive that works by Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.. BYSANTI is a Prostaglandin Analog (Ophthalmic) that works by Ig G1κ monoclonal antibody that binds to the neonatal Fc receptor (Fc Rn), reducing Fc Rn-mediated recycling of Ig G, thereby lowering circulating Ig G levels including pathogenic Ig G autoantibodies.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALESSE and BYSANTI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALESSE is: One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.. The standard adult dose of BYSANTI is: Initial dose 2 mg subcutaneously twice daily; after 3 months, increase to 4 mg subcutaneously twice daily based on clinical response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALESSE and BYSANTI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALESSE is classified as Category C. Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Seco. BYSANTI is classified as Category C. No human data; animal studies insufficient. Based on mechanism (CGRP receptor antagonist), theoretical risk of fetal harm; avoid use in pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.